Business
Ratio Therapeutics Raises $70M to Push Its Targeted Cancer Radiotherapies
Lilly and Bristol Myers both on the cap table. In a field where the drug decays while you ship it, manufacturing is the moat.
Vaccines
EMA Begins Review of Pfizer and Valneva’s Lyme Disease Vaccine, a Potential First
There has been no human Lyme vaccine for two decades — one was withdrawn in 2002 amid safety claims never substantiated. A 9,437-person Phase 3 now sits with the EMA.
Latest news
Regulatory
FDA Halts Regenxbio’s Hunter Syndrome Gene Therapy Again Over Spine Scan Findings
Masses on the spines of five patients treated three to six years ago. All asymptomatic, nature unconfirmed — and the second hold on a Regenxbio programme this year.
Research
Mapping Heart-Transplant Rejection Cell by Cell Reveals Hidden Differences
Two biopsies graded identically can be biologically different. That gap explains why some transplant patients fail the treatment the grade prescribes.
Research
A Redesigned Antibody Could Let Pregnant Patients Take Biologic Drugs More Safely
The placenta actively ferries antibodies to the fetus using one receptor — and mostly leaves albumin behind. Fusing the two exploits that difference.
Business
Argenx to Buy Forte Biosciences for $2.2 Billion, Adding a First-in-Class Antibody
$2.2 billion for a Phase 1b asset. What is being bought is a target — CD122 — and the claim that it opens onto many diseases.
Business
BeOne and Revolution Medicines Team Up on RAS-Driven Cancer Combinations
Four RAS(ON) inhibitors paired with a PRMT5 inhibitor and a trispecific antibody. BeOne funds and runs a global Phase 3; Revolution keeps everything outside select Asian markets.
Regulatory
FDA Approves Lantheus’s Tauklarify, a Brain-Scan Agent That Maps Alzheimer’s Tau Tangles
Amyloid imaging shows whether Alzheimer’s pathology is present. Tau imaging shows how far it has spread — and tau tracks with symptoms in a way amyloid does not.
Vaccines
Two New TB Vaccines Prove Safe but Fall Short of Broad Protection in Large India Trial
Two vaccines, 12,717 participants, 38 months. Some real protective signals in specific groups — and no protection at all in underweight people, which is where TB concentrates.
Business
Amazon Adds Virtual Speech Therapy to Its Health Benefits Marketplace
About 1 in 14 US children has a speech disorder and roughly 40% get no support. Amazon’s pitch is not new therapy capacity — it is telling people the benefit they already have exists.
Regulatory
FDA Approves Regeneron’s Pasatru for Ultra-Rare ‘Stone Man Disease’
About 900 people worldwide have a disease that turns muscle into bone. Pasatru cut new lesions by up to 90% — the second therapy ever approved for it.
Health
For Untreated HIV, a Two-Drug Regimen Matched Three Drugs on Immune Recovery
Three drugs was never a biological requirement. It was insurance against resistance — and modern drugs made the insurance less necessary.